ClinicalTrials.gg
CompletedNCT02954172Updated Dec 8, 2020Results posted

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

A Phase 3 interventional study of Bevacizumab in Combination With Paclitaxel/Carboplatin and IBI305 in Combination with Paclitaxel/Carboplatin in NSCLC, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A randomized, double blind, multicenter phase3 study .

Read the detailed description

A randomized, double blind, multicenter phase3 study in chemotherapy naive patients with stage IIIB,IV or recurrent NSCLC of non-squamous. the study will randomize about 436 patients at a 1:1 ratio to 2 treatment arms. The study is divided 4 phase, screening, combination treatment, maintenance and follow up.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signed inform consent form(ICF)
  2. Age ≥ 18 years and ≤ 75 years, male or female
  3. or cytologically documented inoperable, local advanced (stage IIIB), (stage IV), or recurrent non-squamous NSCLC; Mixed tumors should be categorized according to the predominant cell type
  4. Histologically confirmed epidermal growth factor receptor (EGFR) wild type or insensitive mutation
  5. At least one according to (RECISIT) v 1.1
  6. (ECOG) performance status of 0 or 1
  7. ≥ 6 months
  8. Laboratory results:

    1. Adequate hematologic function, defined as ≥1.5×10\^9 /L, count ≥100 ×10\^9 /L, ≥90g/L;
    2. Adequate liver function, defined as total levels ≤ 1.5 times normal upper limit (), and (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN, or AST and ALT levels ≤ 5 times ULN for patients with hepatic metastasis;
    3. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or ≥ 50 ml / min (Cockcroft-Gault formula) and proteinuria \< 2+;
    4. Coagulation function is adequate, defined as (INR) or prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN), PTT or aPTT ≤ 1.5 times ULN;
  9. Expected protocol compliance
  10. Patients of must agree to use effective measures during study treatment and for 6 months after receiving last study treatment (e.g. abstinence, sterilization surgery, oral contraceptives, contraception by progesterone injection or subcutaneous).

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy or target therapy with another systemic anti-cancer agent (e.g., monoclonal antibody, tyrosine kinase inhibitor) for the treatment of the patient's current stage of disease (Stage IIIB not amenable for combined modality treatment, stage IV or recurrent disease). Prior surgery and irradiation is permitted, provided that the criteria outlined in the protocol for both treatments are met. Disease progressed within 6 months after therapy must be excluded.
  2. Mixed non-small cell and small cell carcinoma, or mixed adenosquamous carcinomas with predominant squamous cell
  3. or cytologically confirmed EGFR sensitive mutation type, unknown EGFR status for any reason is allowed in this study.
  4. Known hemoptysis within 3 months prior to screening with blood volume more than 2.5 mL each time
  5. Evidence of tumor invading major blood vessels on imaging. The investigator or the local radiologist must exclude evidence of tumor that is fully contiguous with, surrounding, or extending into the lumen of a major blood vessel (e.g., pulmonary artery or superior vena cava)
  6. Evidence of , spinal cord compression or carcinomatous meningitis history with clinical symptoms. For stable patients with no symptom, could be admitted if fulfill all below criteria: (s) out of CNS, no at mesocephalon, annular protuberance, medulla oblongata and spinal cord; no history of intracranial bleeding.
  7. Radical radiotherapy to the thorax with curative intent within 28 days prior to enrollment; palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to first dose of study treatment.
  8. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of the study.
  9. Minor surgery (Including insertion of an indwelling catheter) within 48 hours prior to first dose of study treatment
  10. Recent or current (within 10 days prior to first dose of study treatment) receive treatment of Aspirin (> 325 mg/day) or other non-steroidal anti-inflammatory drugs (NSAID) known to inhibit function (within 10 days prior to first dose of study treatment)
  11. Recent or current receive treatment of oral all doses of oral or parenteral anticoagulants or thrombolytic agent. Prophylactic use of anticoagulants is permitted.
  12. History or evidence of inherited bleeding diathesis or coagulopathy or thrombus
  13. Uncontrolled hypertension (SBP>140 mmHg and/or diastolic blood pressure>90 mmHg), prior history of hypertensive crisis and hypertensive encephalopathy
  14. cardiovascular disease but not limited to active infections; unstable angina; stroke or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening) ; congestive heart-failure ( (NYHA) class≥ II) ; serious cardiac arrhythmia, hepatic, renal or metabolic disease requiring medication during the study.
  15. History of peptic ulcer, gastrointestinal perforation, erosive esophagitis, erosive gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula or intra-abdominal abscess within 6 months prior to screening
  16. Patient diagnosed with a tracheo-esophageal fistula
  17. Clinically significant third space effusion (e.g., uncontrolled ascites or pleural effusion by extraction or other treatment)
  18. Pulmonary fibrosis or active pneumonia showed by CT at baseline
  19. Active other than non-small cell lung cancer (NSCLC), treated carcinoma in situ of the cervix, superficial basal cell or squamous cell carcinoma, radical surgery of localized prostate cancer, radical surgery of ductal carcinoma in situ within 5 years prior to randomization
  20. Known disease
  21. Known positive HbsAg and virus (HBV)-DNA drop test in peripheral blood ≥ 1 x 10\^3 copy number/L or 200 IU/mL; If HBsAg positive and HBV-DNA drop test in peripheral blood \< 1 x 10\^3 copy number/L or 200 IU/mL, patient is considered to be eligible by investigator only when chronic hepatitis B in the plateau and do not increase the risk
  22. Known positive or virus (HCV) or syphilis
  23. Known allergic disease or allergic physique
  24. Treatment with any other agent or participation in another clinical trial within 30 days prior to screening
  25. Known alcoholism or drug abuse
  26. Pregnant or anticipation of pregnant during the study or lactating women
  27. Known to bevacizumab or any of its and/or any of the chemotherapy agents
  28. Other conditions that the investigator thinks unsuitable in this study
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    Bevacizumab in Combination With Paclitaxel/Carboplatin

    Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

    Drug: Bevacizumab in Combination With Paclitaxel/Carboplatin

  • Active comparator
    IBI305 in Combination with Paclitaxel/Carboplatin

    Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

    Drug: IBI305 in Combination with Paclitaxel/Carboplatin

Interventions

  • DrugBevacizumab in Combination With Paclitaxel/Carboplatin

    Drug pages: Bevacizumab · Paclitaxel · Carboplatin

    Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

    Also known as: Avastin

  • DrugIBI305 in Combination with Paclitaxel/Carboplatin

    Drug page: IBI305

    Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

    Also known as: Bevacizumab Biosimilar

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    ORR(objective response rate)was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR.

    Time frame: 18 weeks

Secondary outcomes

  1. Overall Survival Time

    OS was defined as the time from randomization to death due to any cause.

    Time frame: 18.020 months

  2. Progression-free Survival

    Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Time frame: 18 months

07

Results

Posted Dec 8, 2020

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/Carboplatin
Started226224
Completed220221
Not completed63
Withdrew: Protocol violation30
Withdrew: Allergic reaction21
Withdrew: Non-measurable lesions at baseline12

Outcome measures

PrimaryObjective Response Rate

ORR(objective response rate)was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR.

Time frame:
18 weeks
Reported as:
Number · percentage of participants
Objective Response Rate
percentage of participantsBevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/Carboplatin
Objective Response Rate46.444.3
Statistical analysis
  • Bevacizumab in Combination With Paclitaxel/Carboplatin vs IBI305 in Combination With Paclitaxel/Carboplatin · Odds ratio (or): 0.90 · 90% CI 0.756 to 1.077
SecondaryOverall Survival Time

OS was defined as the time from randomization to death due to any cause.

Time frame:
18.020 months
Reported as:
Median · month
Overall Survival Time
monthBevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/Carboplatin
Overall Survival TimeNA (NA to NA)18.020 (16.73 to NA)
Statistical analysis
  • Bevacizumab in Combination With Paclitaxel/Carboplatin vs IBI305 in Combination With Paclitaxel/Carboplatin · Log Rank · p = 0.7066
SecondaryProgression-free Survival

Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame:
18 months
Reported as:
Median · months
Progression-free Survival
monthsBevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/Carboplatin
Progression-free Survival8.260 (6.810 to 8.500)8.430 (7.170 to 9.590)
Statistical analysis
  • Bevacizumab in Combination With Paclitaxel/Carboplatin vs IBI305 in Combination With Paclitaxel/Carboplatin · Log Rank · p = 0.3497

Adverse events

Collected over through study completion, an average of 2 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab in Combination With Paclitaxel/Carboplatin5/226 (2.2%)85/226 (37.6%)222/226 (98.2%)
IBI305 in Combination With Paclitaxel/Carboplatin6/224 (2.7%)75/224 (33.5%)216/224 (96.4%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventBevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/Carboplatin
Platelet count decreasedInvestigations27/22624/224
Decreased platelet countInvestigations27/22624/224
Neutrophil count decreasedInvestigations13/2266/224
Neutrophils count decreasedInvestigations13/2266/224
Lung infectionInfections and infestations7/22611/224
pulmonary infectionInfections and infestations7/22611/224
White blood cell count decreasedInvestigations10/2267/224
Lower white blood cell countInvestigations10/2267/224
AnaemiaBlood and lymphatic system disorders8/2264/224
AnemiaBlood and lymphatic system disorders8/2264/224
Most frequent other events
Showing 10 of 26
Most frequent other events
EventBevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/Carboplatin
White blood cell count decreasedInvestigations179/226161/224
Neutrophil count decreasedInvestigations169/226158/224
Platelet count decreasedInvestigations98/226113/224
AnaemiaBlood and lymphatic system disorders54/22653/224
NauseaGastrointestinal disorders52/22631/224
ConstipationGastrointestinal disorders50/22644/224
FeverGeneral disorders33/22620/224
DiarrheaGastrointestinal disorders30/22620/224
HypoesthesiaNervous system disorders24/22625/224
HypertensionVascular disorders25/22625/224

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/CarboplatinTotal
Mean (SD)57.6 ± 8.6957.2 ± 9.2857.4 ± 8.98
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/CarboplatinTotal
Female8379162
Male137142279
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/CarboplatinTotal
Han217211428
Others4913
Region of Enrollment
Region of Enrollment(participants)Bevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/CarboplatinTotal
China220221441
Height
Height(centimeter)Bevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/CarboplatinTotal
Mean164.93 ± 8.166164.03 ± 7.829164.48 ± 8.003
Weight
Weight(kilogram)Bevacizumab in Combination With Paclitaxel/CarboplatinIBI305 in Combination With Paclitaxel/CarboplatinTotal
Mean62.16 ± 10.84462.14 ± 10.27262.15 ± 10.550
08

Study locations

1 site
  • Cancer Center; Sun Yat sen University;
    Guangzhou, Guangdong 510060, China
09

References and documents

Publications

  • Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, Song Y, Zhang C, Mei X, Cao B, Yang L, Cheng Y, Ying K, Sun T, Ren B, Yu Q, Liao Z, Pei Z, Wang M, Zhou J, Yu S, Feng G, Wan H, Wang H, Gao S, Wang J, An G, Geng Y, Ji Y, Yuan Y, Ma S, Jia Z, Hu M, Zhou H, Yu J, Sun X, Zhang L. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2019 Dec;8(6):989-999. doi: 10.21037/tlcr.2019.12.23. PubMed 32010577 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Oct 2018, 22 months.

Results were first posted in Dec 2020, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2016
First posted
Nov 3, 2016
StartActual
Nov 28, 2016
Primary completionActual
Oct 19, 2018
CompletionActual
Nov 12, 2019
Results first posted
Dec 8, 2020
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02954172
Collaborators
WuXi CDS Clinical Research (Shanghai) Co.Ltd.
Responsible party
Sponsor
First posted
Nov 3, 2016
Start date
Nov 28, 2016
Primary completion
Oct 19, 2018
Completion
Nov 12, 2019
Results posted
Dec 8, 2020
Last update
Dec 8, 2020

Study contacts

Li Zhang, Doctor
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Paclitaxel · Carboplatin

Start the discussion